Global scales for cognitive screening in Parkinson's disease: Critique and recommendations
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Cognitive impairment is a common nonmotor manifestation of Parkinson's disease, with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains to severe dementia. The International Parkinson and Movement Disorder Society commissioned the assessment of the clinimetric properties of cognitive rating scales measuring global cognitive performance in PD to make recommendations regarding their use. Methods: A systematic literature search was conducted to identify the scales used to assess global cognitive performance in PD, and the identified scales were reviewed and rated as “recommended,” “recommended with caveats,” “suggested,” or “listed” by the panel using previously established criteria. Results: A total of 12 cognitive scales were included in this review. Three scales, the Montreal Cognitive Assessment, the Mattis Dementia Rating Scale Second Edition, and the Parkinson's Disease‐Cognitive Rating Scale, were classified as “recommended.” Two scales were classified as “recommended with caveats”: the Mini‐Mental Parkinson, because of limited coverage of executive abilities, and the Scales for Outcomes in Parkinson's Disease‐Cognition, which has limited data on sensitivity to change. Six other scales were classified as “suggested” and 1 scale as “listed.” Conclusions: Because of the existence of “recommended” scales for assessment of global cognitive performance in PD, this task force suggests that the development of a new scale for this purpose is not needed at this time. However, global cognitive scales are not a substitute for comprehensive neuropsychological testing. © 2017 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 1×
“Montreal Cognitive Assessment Scale description: The MoCA was originally developed as a screening measure for MCI in the general population.(10) There are other versions of the scale including alternate versions (3 versions total), a “basic” version that aims to test people who are illiterate or have a low educational…”
MethodClinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609 · cited 8×
“A global cognitive scale, such as MoCA, SCOPACOG, DRS-2, or PD-CRS, is sufficient for testing PD-MCI at level I, based on the previously published recommendations.(8) However, this does not allow further differentiation of PD-MCI subtypes, in which more detailed cognitive testing with at least 2 tests per cognitive do…”
BackgroundMethodSelf-citationMioshi, E., Dawson, K., Mitchell, J., Arnold, R., & Hodges, J. R. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1610 · Cited by 2,016
Cognitive profile of patients with newly diagnosed Parkinson disease
Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005) · Neurology · doi:10.1212/01.wnl.0000180516.69442.95 · Cited by 1,007
Self-citationThe effect of age of onset of PD on risk of dementia
Aarsland, D., Kvaløy, J. T., Andersen, K., Larsen, J. P., Tang, M. X., Lolk, A., Kragh-Sørensen, P., & Marder, K. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0234-8 · Cited by 162 · cited 1×
“of disease duration,(4) with increasing age a significant predictor.(5) The presence of PD-D may lead to significant loss of functional independence, worsened quality of life, increased psychiatric comorbidity, increased caregiver burden, earlier nursing home placement, and increased mortality risk.”
Background
Cited by
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Self-citationTMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia
Tropea, T. F., Mak, J., Guo, M. H., Xie, S. X., Suh, E., Rick, J., Siderowf, A., Weintraub, D., Grossman, M., Irwin, D., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25486 · Cited by 83
“In subsequent analyses, a total Mattis Dementia Rating Scale-2 (DRS-2) score of ≥130 or Montreal Cognitive Assessment (MoCA) score of ≥20 at baseline was an inclusion criterion to exclude any subject with PD dementia.(18) A minimum of 0.”
BackgroundSelf-citationZhang, P., Huang, P., Li, Y., Du, J., Luo, N., He, Y., Liu, J., He, G., Cui, S., Zhang, W., et al. (2024) · Aging and disease · doi:10.14336/ad.2023.0518 · Cited by 30
Snyder, A., Gruber-Baldini, A. L., Rainer von Coelln, F., Savitt, J. M., Reich, S. G., Armstrong, M. J., & Shulman, L. M. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-212705 · Cited by 20
Metadata
- Authors
- Skorvanek, M., Goldman, J. G., Jahanshahi, M., Marras, C., Rektorova, I., Schmand, B., van Duijn, E., Goetz, C. G., Weintraub, D., Stebbins, G. T., Martinez‐Martin, P., & the members of the MDS Rating Scales Review Committee
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2017-11-23
- Volume
- 33
- Issue
- 2
- Pages
- 208-218
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2769410386
- Cited by
- 229
- References
- 6
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.